TY - JOUR T1 - Oestrogen plus progestogen increased risk of breast cancer in postmenopausal women JF - Evidence Based Medicine JO - Evid Based Med SP - 172 LP - 172 DO - 10.1136/ebm.8.6.172 VL - 8 IS - 6 A2 - , Y1 - 2003/11/01 UR - http://ebm.bmj.com/content/8/6/172.abstract N2 - (2003) JAMA 289, 3243. Chlebowski RT, Hendrix SL, Langer RD, et al.. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative Randomized Trial.. ;. :. –53.OpenUrlCrossRefPubMedWeb of Science
 
 QUESTION: In postmenopausal women, does oestrogen plus progestogen hormone therapy (HT) increase the risk of abnormal mammographic results and diagnoses of breast cancer? Randomised (allocation concealed*), blinded (clinicians, participants, data collectors, outcome assessors, and monitoring committee),* placebo controlled trial with a mean 5.6 year follow up (Women’s Health Initiative [WHI]). 40 US clinical centres. 16 608 postmenopausal women who were 50–79 years of age (mean age 63.3 y). Exclusion criteria were previous hysterectomy, breast cancer, or probable survival <3 years. Follow up data were available for 15 931 women (95.9%). Women were allocated to 1 daily tablet of conjugated equine oestrogen, 0.625 mg, and medroxyprogesterone acetate, 2.5 mg (n=8506), or placebo (n=8102). Incidence of breast cancer (total, invasive, and in situ) and abnormal mammogram results. Analysis was by intention to treat. Women … ER -